News
Local
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate News
Hot Property
eNewspaper
________________
Subscriptions
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
About Us
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Events
Advertising
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Jobs
CaregiverSD
Community papers
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Games, Puzzles, and Crossword
Crossword
Sudoku
Crossword
Sudoku
Obituaries
Death Notices
Place an obituary
Death Notices
Place an obituary
U-T En Español
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Privacy and Terms
Privacy
Terms
Advertising terms
Privacy
Terms
Advertising terms
Copyright © 2022, The San Diego Union-Tribune |
CA Notice of Collection
|
Do Not Sell My Personal Information
Sections
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate
Obituaries
eNewspaper
Newsletters
Show Search
Search Query
Submit Search
COVID-19
For subscribers
Phenomenal women
Latino life
Crossword
Sudoku
About Us
Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Diego Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Kezar Life Sciences Inc
(NQ:
KZR
)
0.7898
-0.0340 (-4.13%)
Streaming Delayed Price
Updated: 12:57 PM EDT, Oct 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Kezar Life Sciences Inc
< Previous
1
2
3
4
Next >
Penny Stock Kezar Life Sciences Rejects Acquisition Deal From Concentra Biosciences At $1.10/Share, Shelves Mid-Stage Lupus Nephritis Study
October 17, 2024
Kezar Life Sciences halted its PALIZADE Phase 2b lupus nephritis trial due to fatal adverse events. Meanwhile, its PORTOLA Phase 2a autoimmune hepatitis trial progresses, with topline data expected in...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
October 09, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
October 09, 2024
Via
Benzinga
Why Saratoga Investment Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
October 09, 2024
Via
Benzinga
Analyst Expectations for Kezar Life Sciences's Future
November 27, 2023
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
October 08, 2024
Via
Benzinga
FDA Put Brakes On Penny Stock Kezar Life Sciences' Mid-Stage Study For Lead Development Candidate After Patient Deaths
October 07, 2024
Kezar Life Sciences' zetomipzomib drug for lupus nephritis has been placed on clinical hold by the FDA following serious safety concerns. The company continues its autoimmune hepatitis trials while...
Via
Benzinga
Exposures
Product Safety
12 Health Care Stocks Moving In Friday's Intraday Session
October 04, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
September 30, 2024
Via
Benzinga
Kezar Life Sciences Discontinues Unpromising Phase 1 Solid Tumor Drug
August 14, 2024
Kezar Life Sciences announced it has stopped enrollment in its phase 1 solid tumor drug study and will focus on developing zetomipzomib for autoimmune diseases.
Via
Benzinga
KZR Stock Earnings: Kezar Life Sciences Beats EPS for Q2 2024
August 13, 2024
KZR stock results show that Kezar Life Sciences beat analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
KZR Stock Earnings: Kezar Life Sciences Beats EPS for Q1 2024
May 09, 2024
KZR stock results show that Kezar Life Sciences beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
From Pennies to Fortunes: 3 Stocks Set to Make Millionaires
March 27, 2024
Discover how these stocks to make millionaires are leading in the gold, biotechnology, and application software industries.
Via
InvestorPlace
Diamonds in the Dust: 3 Penny Stocks Set to Soar 500% by 2026
March 16, 2024
Learn how these penny stocks may yield a 5X return with their lead in application software and biotechnology.
Via
InvestorPlace
KZR Stock Earnings: Kezar Life Sciences Misses EPS for Q4 2023
March 14, 2024
KZR stock results show that Kezar Life Sciences missed analyst estimates for earnings per share the fourth quarter of 2023.
Via
InvestorPlace
Week In Review: Mabwell Sells Ex-China Rights To Rare Disease Therapy In $412 Million Deal
March 02, 2024
Mabwell, a Shanghai-San Diego biotech, sold ex-China rights for 9MW3011 to Disc Medicine of Watertown, MA in a deal worth up to $412 million. Meanwhile, AstraZeneca has returned most of the global...
Via
Talk Markets
3 Top Penny Stocks for 5,000% Upside in 2024 and Beyond
February 25, 2024
When you want to light your afterburners, these ideas will do the trick.
Via
InvestorPlace
3 Penny Stocks Poised for an Unbelievable 1,000% Jump
February 02, 2024
Discover penny stocks with the potential for a 1,000% leap: strategic growth, debt-free stability and pharmaceutical innovation await.
Via
InvestorPlace
As Oversupply Deflates Lithium Bubble, IPO Market Keeps In High Spirits
January 08, 2024
Lithium market facing persistent turmoil as spot prices decline for more than a year. But asset management firm Janus Henderson sees a silver lining.
Via
Benzinga
Topics
Initial Public Offering
Exposures
Securities Market
Bull Run Bonanza: Top 3 Penny Stocks Primed for Explosive Growth
December 18, 2023
Are you looking for the next bull run bonanza? Here are the top three penny stocks primed for explosive growth.
Via
InvestorPlace
Week In Review: Everest Acquires Novel Autoimmune Therapy In $132 Million Agreement
September 23, 2023
Shanghai Everest Medicines acquired China/Asian rights to a novel therapy for autoimmune diseases from Kezar Life Sciences of South San Francisco in a deal worth $132.5 million. The company will make...
Via
Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For October 5, 2023
October 05, 2023
Via
Benzinga
Why Murphy Canyon Acquisition Shares Are Trading Higher By Around 32%; Here Are 20 Stocks Moving Premarket
September 21, 2023
Gainers Near Intelligence, Inc. (NASDAQ: NIR) shares rose 34.1% to $0.2801 in pre-market trading after falling 42% on Wednesday. Near Intelligence recently named its General Counsel, Jay Angelo, to...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
August 22, 2023
Via
Benzinga
Top 5 Health Care Stocks That Could Blast Off This Month
August 21, 2023
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
August 15, 2023
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
August 11, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 11, 2023
August 11, 2023
Via
Benzinga
Why Maxeon Solar Technologies Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Friday's Mid-Day Session
August 11, 2023
Gainers Amyris, Inc. (NASDAQ: AMRS) shares jumped 179.1% to $0.1839. Amyris shares dipped over 80% on Thursday after the company announced it filed for Chapter 11 bankruptcy.
Via
Benzinga
Topics
Bankruptcy
Exposures
Financial
Legal
Stocks That Hit 52-Week Lows On Thursday
July 27, 2023
During Thursday, 56 stocks hit new 52-week lows.
Via
Benzinga
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.